This review discusses the metabolism of arachidonic acid to prostaglandins (PG) and other metabolites and the site of physiological action of these products along the nephron.
Cyclooxygenase activity. Changes in cell cyclooxygenase activity (half-life 24 hr) may occur slowly under certain conditions and can chronically change the capacity for PG synthesis.
Such alterations in total cyclooxygenase activity have been observed, for example, in rats with congenital diabetes insipidus after chronic administration of antidiuretic hormone [4] . A different mechanism may underlie the increase in cyclooxygenase after unilateral ureteral ligation [5] [6] [7] [8] or renal venous obstruction [91. In these instances it appears that the increase in enzyme does not occur in the renal cells, themselves, but is instead due to proliferation of inflammatory cells [10] . Substrate availability. Under normal physiological conditions the amount of free intracellular AA, that is available for cyclooxygenase is negligible [1] . Apart from the activity of cyclooxygenase in a given tissue, the major factor controlling PG-synthesis is the availability of free AA. AA is esterified in the 2 position of the phospholipid, predominantly in phosphatidylinositol but also in phosphatidyleholine and phosphatidylethanolamine.
Most likely both phospholipase C and phospholipase A2 activation are involved in the release of AA [11] [12] . Agreement exists that the enzymatic steps leading to the release of AA are calcium-dependent [1] . Phospholipase A2 in the renal medulla [12] [13] [14] may be a calcium-calmodulin-dependent enzyme, while phospholipase C appears to be calmodulin-independent [15, 161. In the isolated kidney [17] and kidney slices [7] and cultured mesangial cells [181, there are specific pools of AA linked to cyclooxygenase activity, while other AA pools are unrelated to PG-synthesis. Furthermore, metabolism of only a small percentage of the AA pool in phospholipids seems to be hormone responsive [7, 181. The amount of membrane-bound AA converted to cyclooxygenase or lipoxygenase products is only a small fraction of the total. Only a few percent of the cellular AA is released even after maximal hormone stimulation, and of this, only a fraction (10 to 40%) is transformed by cyclooxygenase, while the rest may be reincorporated into phospholipids [17] . The fact that the hormone responsive AA pool is small compared to the total phospholipid-bound AA complicates studies which rely on the prelabeling of phospholipids with exogenous AA, because under most conditions the total phospholipid pool is labeled nonspecifically [7] . Prelabeling of the specific hormone responsive pool may be facilitated by prior hormone stimulation [19] . Further complicating matters, different individual phospholipids also have different turnover rates and are represented to differing degrees within the cells. For example, phosphatidylinositol only represent 5 to 10%, while phosphatidylcholine and phosphatidylethanolamine each account for about 30% of the total phospholipids. Thus, small changes in the turnover of phosphatidyicholine and phosphatidylethanolamine may release as much AA as much more marked changes in phosphatidylinositol turnover. For all these reasons, the exact source of AA and the mechanism of its release have yet to be defined fully.
Inhibition of phospholipase. An endogenous inhibitor of phospholipase has been described in neutrophils [20-22] and renal medulla [22] . This inhibitor is a protein that is synthetized and released in response to glucocorticoids. It has been called macrocortin [20] , lipomodulin [21] , orrenocortin [22] . Lipomodulin has been shown to inhibit both phospholipase A2 and C in vitro [21] .
Other factors influencing AA availability. In addition to release of AA by phospholipase, factors that influence the AA availability include:
(1) Binding of AA to protein. AA avidly binds to both extra and intracellular proteins and as such is no longer available for cyclooxygenase. Thus, not all intracellular AA is "free" and can be utilized for PG synthesis [1].
(2) Reincorporation of AA. AA released from the phospholipids may be reincorporated rapidly into phospholipids [1, 17] . This reaction competes with cyclooxygenase for AA [7, 18] . As the reincorporation into phospholipids requires ATP, the reaction may be slowed during hypoxia, which, in turn, could lead to higher concentrations of nonesterified AA. This (3) Competition forAA. In addition to cyclooxygenase, AA is also a substrate for lipoxygenase and epoxygenase. This competition for free AA could influence PG-synthesis. Furthermore, the products of these enzymes may in turn influence phospholipases and the cyclooxygenase system. These pathways are only beginning to be explored in the kidney.
Lipoxygenase products and the kidney Formation of lipoxygenase products by the kidney. Arachidonic acid can also be metabolized via lipoxygenase pathways ] demonstrated formation of 12-HETE and 15-HETE (identified by gas chromatography followed by mass spectrometry) by a cytosolic preparation from rabbit renal medulla but not from the cortex. The lipoxygenase activity was increased in hydronephrotic kidneys, a finding similar to the increase in cyclooxygenase activity in hydronephrotic kidneys [5] . In the hydronephrotic kidney, it remains unclear whether these products are truly of renal cell origin or are produced by invading inflammatory cells [10] . The enzyme required calcium and was inhibited by the lipoxygenase inhibitors eicosatetraynoic acid (ETYA) and phenidone, but not by indomethacin [28] .
Lipoxygenase products have been identified lately by gas chromatography-mass spectrometry as 12-HETE in rat glomeruli [29, 301 and as 12-and 15-HETE in human glomeruli [30] .
It is to be expected that lipoxygenase products will be identified in other renal structures, as more attention is directed toward these products and as analytical detection methods are improving. The physiological significance of these lipoxygenase products in renal function remains to be determined but is certain to attract much interest in the near future. Lately, it has been postulated that lipoxygenase products may play a role in experimental immune injury to the glomerulus [31-33].
Metabolism of leukotrienes in the kidney. To date no evidence exists for 5-HETE formation and subsequent leukotriene production by kidney tissue (Fig. 2 ). Systemic infusion of leukotrienes, however, does influence renal function [34] . It is therefore reasonable to assume that leukotrienes released from inflammatory cells within the kidneys may influence renal hemodynamics and capillary permeability, as they do in other systems [261. Also, the kidney may be involved in the metabolism of leukotrienes. Transformation of LTC3 to the biologically more active LTD3 by gamma-glutamyltranspeptidase has been demonstrated in the kidney [35] . Conversion of LTD to LTE has also been demonstrated in the porcine kidney [36] and is associated with a tenfold decrease in biological activity. In vivo the kidney may play a role in the metabolism and inactivation of leukotrienes as suggested by total body autoradiography of mice after injection of [3H]-labeled leukotriene C3 [37] .
Epoxygenase pathway
In addition to cyclooxygenase and lipoxygenase, the kidney contains mixed function oxidases that are involved in the metabolism of fatty acids and also PG [38] [39] [40] [41] . Recently, it has been shown that AA can be converted by NADPH-dependent, cytochrome P-450 to oxidation products ( Fig. 3 possible that a cytochrome P-450-linked epoxygenase system is involved in the formation of metabolites that previously were mistaken for cyclooxygenase or lipoxygenase products.
An intriguing finding is the production of considerable amounts of AA derivatives by the thick ascending loop of Henle that derive from neither cyclo-nor lipoxygenase pathways and may be epoxygenase products [45] [46] [47] . The epoxygenase pathway is certain to attract considerable interest, especially as 5,6 epoxyeicosatrienoic acid, a product of a renal NADPH-dependent monooxygenase pathway, can inhibit sodium transport in isolated collecting tubules [48] and vasopressin's hydroosmotic action in the toad urinary bladder [49].
PG-synthesis in the kidney
The kidney, and especially the renal medulla, is one of the most active PG-producing tissues. Homogenates or microsomes from the entire kidney produce PGE2, PGF2, 6 keto PGF1,, TXB2, and PGD2 to varying degrees depending on the conditions used [2] . The isolated perfused kidney produces predominantly PGE2 [5, 50] but also can release PG!2 [51], and under certain circumstances, TXB2 [52, 531. Table 2 lists factors influencing renal PG synthesis.
There are marked regional differences in the quantity and pattern of PG production within the kidney. As PGs are locally active agents, the pattern of PGs produced by different nephron Localization of prostaglandin synthase by histochemical or immunofluorescence methods. Localization of prostaglandin synthase activity within the kidney has been performed by histochemical staining for peroxidase activity [71, 72] and indirect immunofluorescence for cyclooxygenase [73] . Both methods have yielded remarkably similar results. In the renal cortex of rabbit, cow, rat, sheep, and guinea pig, positive immunofluorescence for cyclooxygenase was observed in the endothelial cells of arteries and arterioles but not in the capillaries or venous tree [73] . Glomerular epithelial cells of Bowman's capsule stained positive in the rabbit only, whereas in bovine and ovine glomeruli, the fluorescence was present in a mesangial distribution. Proximal tubules, the loop of Henle, and distal convoluted tubules, including the macula densa, were negative by both immunofluorescence and peroxidase methods [71, 72] . It should be considered, however, that the im-munofluorescence staining for cyclooxygenase activity gives only a qualitative picture and a negative staining reaction does not rule out cyclooxygenase activity but could just indicate levels below the detection limit.
In the renal medulla both histochemical and immunofluorescence methods show strongly positive staining in collecting tubule cells and interstitial cells [71-73]. PG-synthesis by different nephron segments. (1) Renal cortex. To better characterize the source of PG synthesis in renal cortical tissue, isolated nephron segments have been examined for PG synthesis. PG!2 synthesis has been shown to be prominent in microdissected cortical arteries and arterioles [74] . Rat glomeruli produce mainly PGE2 and PGF2,, and less PGI2 and At present there is convincing evidence that prostaglandins 89 influence: (1) renal blood flow and glomerular filtration, (2) the 90 release of renin, and (3) the urinary concentrating mechanism.
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Prostaglandins may affect renal blood flow to varying degrees tion rate (GFR) [117, 121, 122, 125] . They may do so by changing the afferent and efferent arteriolar resistance [121, 125] , by influencing the renin-angiotensin system [117, 121, 125] , and finally, by directly affecting the glomerular filtration characteristics via changes in mesangial contraction [122] . The glomerulus can decrease its size in response to various vasoactive agents [122, 126] Angiotensin 11
Converting enzyme inhibitor Hydrogen peroxide Mercury chloride A23 187 Angiotensin 11
Vasopressin Platelet activating factor Bradykinin Zymosan A23 187 Angiotensin II Vasopressin stain or immunofluorescence for cyclooxygense in this tubular segment. Table 3 summarizes factors known to influence PG synthesis in isolated glomeruli and cultured glomerular cells.
(2) Renal medulla. In agreement with the histochemical and immunofluorescent studies, the major sources of PGE2 production within the medulla are collecting tubules and interstitial cells. Both rabbit interstitial cells in culture [96-99] and isolated or cultured [100-103] collecting tubule cells very actively produce PG, predominantly PGE2, and to a lesser extent, PGF2. Table 4 indicates agents that alter PG synthesis in collecting tubules and medullary interstitial cells.
Physiological and pathophysiological considerations
The physiological role of prostaglandins in modifying various renal functions has become increasingly apparent over the last plete review of the effects of PG-synthesis inhibitors on renal function refer to [129, 130] .) The possibility that imbalances between vasodilatory PG and the vasoconstrictor thromboxane play a role in renal diseases has also been raised based on results with experimental unilateral ureteral obstruction [5, 6, 131] , acute renal failure [52, 91, 132] , renal transplant rejection [133] , and experimental nephrotoxic serum nephritis [134] . Changes in intraglomerular hemodynamics can significantly influence the filtration, deposition, and subsequent handling of macromolecules (for example, proteins and immune complexes) by the glomerulus [135] . Thus, vasoactive agents could hfluence glomerular immune-injury; this process could, in turn, be modulated by intraglomerular production of PGs [94] .
PG and the control of renin release. PGs, particularly PGE2 and PGI2, have been demonstrated to enhance plasma renin activity in vivo and directly increase renin release in vitro and thus represent one of the multiple factors controlling renin (for review, see [1361).
In vitro studies showed that locally produced PGs act on renin secretion by renal cortical preparations [1361. Stimulation of renin release also occurs in isolated glomeruli superfused with arachidonic acid PGE2 or PG!2 [137] , and this is blocked by PG synthesis inhibition. The mechanism of action of PGs on renin release seems to involve cyclic AMP as second messenger [138] and both PGE2 and PGI2 stimulate cyclic AMP generation in rat [139] and human glomeruli [140] .
PG in the urinary concentrating mechanism. Ever since the original observation that PGE1 inhibits the effect of antidiuretic hormone in the toad urinary bladder [1411 and in the mammalian collecting tubule [142] , the interaction of ADH with PG has attracted much interest. Multiple studies have confirmed that PGE1 and PGE2 antagonize the antidiuretic action of ADH both in vitro and in vivo. [143-1451. Two major questions that have attracted considerable interest are: (1) How does PG interfere with the renal concentrating mechanism? (2) Does ADH directly enhance the synthesis of prostaglandins in its target organ closing a negative feedback loop?
Concerning the first question, several possible mechanisms exist. PG could interfere with the renal concentrating mechanism by increasing renal medullary blood flow leading to the washout of solute and dissipation of the osmotic gradient required for water reabsorption. PG may also influence medullary solute composition by decreasing sodium transport and urea accumulation in the medulla. Both of these effects could be independent of ADH. Consistent with this formulation, medullary NaCI concentration increases after inhibition of PG synthesis and decreases after administration of PGE2 [146, 147]. Thus, PG could influence medullary solute composition and hence urinary concentrating ability even in the absence of ADH [148] . Also, urea permeability of the toad urinary bladder [149] and the mammalian collecting tubule [150] increases after inhibition of PG synthesis while exogenous PG decreases urea permeability. It has been shown that vasopressin stimulates adenylate cyclase and enhances NaCI reabsorption via cyclic AMP in the medullary thick ascending limb of Henle. Moreover, two laboratories independently have shown that PGE2 inhibits adenylate cyclase and NaCI reabsorption in this nephron segment in a dose-dependent manner in response to vasopressin [151, 152] . Since NaCI reabsorption in this nephron segment is central to the generation and maintenance of the medullary hypertonicity, these data suggest that PGE2 can also affect the urinary concentration mechanism by modifying the action of vasopressin in the thick ascending limb of Henle's loop.
The major effect of PG in the concentrating mechanism is its interference with the cellular mechanism of action of ADH. . Finally, it has been proposed that thromboxane may directly enhance vasopressin's action [159] though these findings remain controversial [160] .
The second question, that is, whether ADH directly enhances the synthesis of prostaglandins in its target organ thereby closing a negative feedback loop as originally proposed by Zusman, Keiser, and Handler [161] , has resulted in some seemingly contradictory answers. In the toad urinary bladder stimulation of PGE2 and thromboxane synthesis after ADH has been reported [159, 161] . Other groups were unable to detect a significant effect of ADH on PGE2 synthesis in the toad bladder or toad bladder epithelial cells [162] [163] [164] . At present it appears that the reason for the differences may in part relate to differences in the preparation of the tissue [165, 166] .
In studies with mammalian tissue, interstitial cells in culture, medullary slices and cell suspensions, collecting tubule cells in culture, and microdissected collecting tubules have been used. In medullary slices and cell suspensions ADH usually stimulates PGE2 synthesis to some extent (see Table 4 ). These preparations do, however, contain both interstitial and collecting tubule cells, and thus, do not allow one to attribute the increase in PGE2 synthesis to a specific cell. In primary cultures of medullary collecting tubule cells ADH increased cyclic AMP concentration but did not stimulate PGE2 synthesis [ A number of points have to be considered to explain these discrepant results. For example, PGE2 synthesis by toad urinary bladder, medullary slices, and isolated collecting tubules decreases progressively with incubation time [14, 105, 163] . The absence of a stable baseline makes it difficult to unequivocably demonstrate stimulation, unless this occurs to a very marked degree. Demonstration of ADH-induced PGE2 synthesis may be complicated further by the fact that cyclic AMP can decrease PG production probably by inhibiting phospholipase activity.
Based on the observation that 8 bromo cyclic AMP can inhibit PGE2 synthesis in renal medullary cells and toad bladder epithelial cells under basal and ADH-stimulated conditions, it has been proposed recently that ADH and PGE2 may interact in a dual feedback loop [1661. In this scheme ADH would increase PGE2 synthesis by activating phospholipases in a cyclic AMPindependent manner as originally proposed by Zusman, Keiser, and Handler [161] . The resulting increase ofPGE2 will, in turn, inhibit ADH's hydroosmotic effect, to a large extent by interfering with cyclic AMP generation. On the other hand, the increase in cyclic AMP could inhibit phospholipase activation and the resulting synthesis of PGE2, representing a second feedback loop that would tend to prevent an overshoot of both the ADH and PGE2 effect in either direction.
Contribution of PG to renal NaC1 excretion. Despite a considerable amount of experimental data from both in vivo and in vitro studies, the evidence for a blood-flow independent role for prostaglandins in renal NaCI excretion remains controversial. In vivo, depending on the experimental conditions (for example, prior NaCI content of diet, volume status, water diuresis, or antidiuresis, awake or anesthesia, and so forth), intrarenal administration of PGE or inhibition of renal PG production has provided results that indicate: (1) renal PG do not influence renal NaCI excretion; (2) PG inhibit NaCI excretion, or (3) PG increase renal NaCI excretion [115, 116, 1671 . These conflicting results are not overly surprising as the physiological status of the animal can alter the effect of prostaglandins on renal blood flow and its distribution. Though some studies attempt to minimize or exclude changes in blood flow, it remains doubtful whether this factor can ever be eliminated adequately during in vivo studies. Studies using urinary PGE2 excretion as an index of renal PG synthesis have occasionally, but not always, shown a correlation between urinary PG and NaCI excretion. of Henle [171] from rabbits, another group has been unable to show such an effect [172, 173] . The reason for these discrepancies remains unclear and cannot be explained easily by differences in hormonal status, basal NaCI transport, or buffers used. If PGE2 produced by the collecting tubule inhibits NaCl transport, it remains unclear why inhibition of collecting tubular PG synthesis does not result in enhancement of NaCI transport.
Holt and Lechene [1741 did, however, report that PG-inhibition prevented the vasopressin-induced changes in Na-transport in cortical collecting tubules. Studies using simultaneous measurements of NaCI transport and PGE2 synthesis by isolated collecting tubules might be helpful in resolving the role of PGE2 in NaCI transport by this segment. Also, it is possible that noncyclooxygenase products of arachidonic acid influence NaCI transport. For example, PGE2 has been postulated to inhibit NaCl transport in the thick ascending limb of Henle's loop [171] . The thick ascending loop of Henle, however, produces only very small amounts of prostaglandins [104, 122, 125] . On the other hand, cells from this segment seem to have a high capacity to metabolize arachidonic acid to noncyclooxygenase products possibly via the epoxygenase pathway [45, 661 . The possibility that such products influence NaCI transport has been reported [48] and will have to be examined further.
Conceivably, the effect of PGE2 on NaCI transport observed in isolated tubules may be an indirect one secondary to an influence of the added PGE2 on the formation of noncyclooxygenase products.
Role of PG in renal phosphate excretion. Published reports on the effects of PGs on renal phosphate transport are also conflicting. Beck et al [175] showed that PGE1 alone was mildly antiphosphaturic but that it markedly inhibited the phosphaturic response to PTH in intact dogs. In contrast, Strandhoy et al [1761 reported that PGE1 increased the fractional excretion of phosphate in intact dogs whereas PGE2 was inactive. In further studies Fragola et al [177] confirmed that PGE2 by itself had no effect on phosphate excretion in thyroparathyroidectomized dogs, but abolished the phosphaturic action of PTH in vivo.
This effect occurred only if PGE2 infusion preceded the administration of PTH. More recently, the same group using the microperfusion technique showed a dual role for PGE2. PGE2, like PTH, inhibited phosphate transport in the proximal straight segment of the rabbit nephron, but also antagonized the effect of PTH [178] . Taken together, these results could suggest that the interaction of PTH and PGE in vivo could represent tubular desensitization to PTH by PGE2.
In rabbit cortical collecting tubules, Holt and Lechene [174] demonstrated that ADH inhibited calcium and phosphorus reabsorption and that pretreatment with meclofenamate blocked this effect of ADH whereas PGE2 mimicked the effect.
From these studies, the authors concluded that phosphate reabsorption in the cortical collecting tubule may be decreased by PGE2 synthesized in response to ADH. In summary some evidence supports a role for PG to inhibit tubular phosphate transport. It should be recalled however, that the proximal tubule, the major site of phosphate transport, has very little capacity to produce PG [76, 77, 86]. Also to date, no unequivocal effect of PG inhibition on proximal tubular phosphate transport has been demonstrated.
Role of PG in renal erythropoeitin production. A role for renal PG in the production and release of erythropoeitin by the kidney has been postulated based on some indirect experimental evidence [179, 180] . Unfortunately, our knowledge of the synthesis of erythropoeitin by the kidney and its control is too scanty at this point to allow a critical evaluation of this issue.
Role of prostaglandins in various renal diseases
Because of the multiple contributions of prostaglandins to various renal functions, it is not surprising that abnormal prostaglandin synthesis has been invoked to contribute to a variety of disease states. In cases of threatened renal function, the enhanced PG synthesis may help to maintain renal blood tors, are, however, associated With a variety of abnormalities of renal function [129, 130] .
Abnormalities of renal PG synthesis have also been observed in experimental hypokalemia [182] [183] [184] , experimental hypercalcemia [185] , and hypothyroidism [186] and were related to the associated inability to maximally concentrate urine. However, these findings have been questioned [187, 188] and the urinary concentrating defect appears independent of changes in PG synthesis [189, 190] . Also, a contributory role of enhanced prostaglandin synthesis in Bartter syndrome has been discussed [191] .
Summary
This very brief summary of the various possible contributions of PG to normal and abnormal renal function should highlight the problem of assigning a specific role to PG in overall renal physiology and pathophysiology. PG produced in specific segments of the nephron will affect specific functions occurring in this segment. These effects need not necessarily be reflected in the overall renal function. Also in some cases, the determinant may not be prostaglandins, that is, cyclooxygenase derivatives of AA, but perhaps lipoxygenase or epoxygenase products that influence the functional parameters of the specific segment.
Despite the multitude of renal functions that may be influenced by PG, we would like to propose a teleological hypothesis for an overall role of PG in the kidney, that is, that of cytoprotective agents. Renal vasodilatatory prostaglandins will maintain renal blood flow when the latter is challenged, thus, preventing hypoxic injury to the tissue. Endogenous prostaglandins may also protect tubular cells from extreme environmental changes as may occur on both the luminal and contraluminal sides. For example, tubular cells may be exposed to luminal fluid that may vary from hypotonic to hypertonic, from alkaline to acid, and so forth. Similarly, the interstitial fluid osmolality and solute composition is subject to considerable variations which may be opposite to those existing on the urinary side. The role of PG might be to maintain the internal milieu of the cells exposed to such extreme changes in environment. This could be accomplished by changing the permeability characteristics of the membranes and the function of pumps. Thus, specific PGs could dampen the hormonal response to protect the specific nephron segment, which might otherwise suffer injury. This hypothesis might also help to explain why the effect of PG administration or inhibition of PG synthesis may vary considerably depending on the overall physiological state of the subject: Maintenance of a local internal milieu may require different responses from those required for total body homeostasis. 
